| Literature DB >> 31500622 |
Hala A Farrag1, Nagwa Abdallah2, Mona M K Shehata3, Ebthag M Awad1.
Abstract
BACKGROUND: This study sought to develop new strategies for reverting the resistance of pathogenic Gram-negative bacilli by a combination of conventional antibiotics, potent permeabilizers and natural beta lactamase inhibitors enhancing the activity of various antibiotics.Entities:
Keywords: Beta lactam resistance; In vitro gamma irradiation; Natural beta lactamase inhibitors; Outer membrane permeability; Pathogenic gram-negative bacilli; Permeabilizers
Mesh:
Substances:
Year: 2019 PMID: 31500622 PMCID: PMC6732830 DOI: 10.1186/s12929-019-0561-6
Source DB: PubMed Journal: J Biomed Sci ISSN: 1021-7770 Impact factor: 8.410
Screening for extended-spectrum β-lactamases (ESBLs) production by certain pathogenic bacterial isolates using different methods
| Isolates no. | Bacterial Species (GNB) | DDST result | MDDT result | Combined disc method | Nitrocefin test result | Production of beta- lactamase | |
|---|---|---|---|---|---|---|---|
| CFP-SCF | PRL-TZP | ||||||
| 1 |
| – | – | – | – | – | non-producer |
| 2 |
| + | + | + | + | + | Producer |
| 3 |
| – | – | – | – | – | non-producer |
| 4 |
| + | + | + | + | + | Producer |
| 5 |
| – | – | – | – | – | non-producer |
| 6 |
| – | – | – | – | – | non-producer |
| 7 | – | – | – | – | – | non-producer | |
| 8 | + | + | + | + | + | Producer | |
| 9 | + | + | + | + | + | Producer | |
| 10 | – | – | – | – | – | non-producer | |
| 11 | – | – | – | – | – | non-producer | |
| 12 |
| – | – | – | – | – | non-producer |
| 13 | + | + | + | + | + | Producer | |
| 14 | – | – | – | – | – | non-producer | |
| 15 | – | – | – | – | – | non-producer | |
DDST Double disk synergy test, MDDT Modified double disk synergy test, CFP Cefoperazone, SCF Cefoperazone sulbactum. PRL Piperacillin, TZP Piperacillin tazobactam, GNB Gram- negative bacilli
Examination of antibacterial activity of some selected permeabilizers (phytochemicals) through agar diffusion method against certain pathogenic Gram-negative bacilli
| Permeabilizers conc. | Microorganisms | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
| |||||||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | |
| Gallic acid | |||||||||||||||
| 500 μg/ml | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 600 μg/ml | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 700 μg/ml | – | – | – | – | – | – | – | – | – | – | – | – | – | – | + |
| Ellagic acid | |||||||||||||||
| 30 μM | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 40 μM | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 50 μM | – | – | – | – | – | – | – | – | – | – | – | – | – | – | + |
| Thymol | |||||||||||||||
| 400 μg/ml | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 500 μg/ml | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 600 μg/ml | – | – | – | – | – | – | – | – | – | – | – | + | – | – | + |
| Chitosan | |||||||||||||||
| 50 ppm | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 100 ppm | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 250 ppm | – | – | – | – | – | + | – | + | – | – | – | – | – | – | – |
| EDTA | |||||||||||||||
| 0.1 mM | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 0.5 mM | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 1 mM | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Sorbic acid | |||||||||||||||
| 2 mM | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 5 mM | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 10 Mm | – | + | – | – | – | – | – | – | – | – | – | + | – | – | + |
(+) susceptibility (in case of disc method inhibition zone > 6 and in case of agar method inhibition zone > 10)
(−) absence of susceptibility
Evaluation of synergistic interaction between some natural beta lactamase inhibitors in association with selected permeabilizers with no antibacterial activity on susceptibility of beta lactamase producer isolates to different beta lactam antibiotics
| Mean inhibition zone (mm) / Susceptibility break points | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Permeabilizers | Ab- alone | ECG | ECG + GA | ECG + T | Quercetin | Q + GA | Q + T | Permeabilizers | Ab-alone | Gallic acid | Thymol |
| aAntibiotics (Ab) | bAntibiotics (Ab) | ||||||||||
|
| |||||||||||
| PRL ≥21 | 6/R | 6/R | 20/M | 23/S | 15/R | 19/M | 24/S | TZP ≥21 | 14/R | 20/M | 26/S |
| CFP ≥21 | 6/R | 6/R | 16/M | 21/S | 16/M | 21/S | 25/S | SCF ≥22 | 14/R | 19/M | 20/M |
|
| |||||||||||
| PRL | 6/R | 6/R | 19/M | 21/S | 16/R | 24/S | 21/S | TZP | 15/R | 20/M | 21/S |
| CFP | 6/R | 6/R | 23/S | 20/M | 16/M | 20/M | 22/S | SCF | 14/R | 22/S | 23/S |
|
| |||||||||||
| PRL | 12/R | 12/R | 16/R | 25/S | 18/S | 22/S | 20/S | TZP | 17/R | 23/S | 26/S |
| CFP | 10/R | 10/R | 15/R | 21/S | 17/M | 20/M | 22/S | SCF | 15/R | 25/S | 21/M |
|
| |||||||||||
| PRL | 6/R | 6/R | 18/S | 19/S | 12/R | 19/S | 21/S | TZP | 11/R | 22/S | 22/S |
| CFP | 6/R | 6/R | 22/S | 25/S | 15/R | 22/S | 24/S | SCF | 12/R | 22/S | 25/S |
|
| |||||||||||
| PRL | 6/R | 6/R | 20/M | 23/S | 15/R | 20/M | 24/S | TZP | 20/M | 30/S | 27/S |
| CFP | 6/R | 6/R | 18/M | 21/S | 18/M | 20/M | 23/S | SCF | 18/M | 25/S | 23/S |
ECG Epigallocatechin gallate, Q Quercetin, GA Gallic acid, T Thymol
aStandard discs of single β-lactam antibiotics PRL (100 μg) = Piperacillin CFP (75 μg) = Cefoperazone
b Standard discs of antibiotics combined with β-lactamase inhibitors
TZP (100/10 μg) = Piperacillin/ tazobactam SCF (75/30 μg) = Cefoperazone/ sulbactam
Effects of gamma irradiation on ESBL production by five ESBLs-producing bacterial strains
| Isolate No./ Species of microorganism | Radiation | Half of inhibition zone (mm) in absence AMC / adjacent to AMC disk (DDST) | Half of inhibition zone (mm) in absence TZP/adjacent to TZP disk (MDDT) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AMC | CTX | CAZ | FEP | ATM | TZP | CAZ | FEP | ||
| 2/ | Before | 5.5 ± 0.5(0.3) | 3 ± 0.5(0.3) /7 ± 0.5(0.3) | 3 ± 0.3 (0.2) /8 ± 0.6 (0.3) | 3 ± 0.2 (0.1) /3 ± 0.6 (0.3) | 3 ± 0.8 (0.5) /3 ± 0.1 (0.1) | 7 ± 0.8 (0.5) | 3 ± 0.2 (0.1) /9 ± 0.2 (0.1) | 3 ± 0.5(0.3) /6 ± 0.5(0.3) |
| After | 6 ± 0.5(0.3) | 3 ± 0.2 (0.1) /7 ± 0.2 (0.1) | 3 ± 0.5(0.3) /8 ± 0.7 (0.4) | 5 ± 0.4 (0.2) /5 ± 0.1 (0.1) | 3 ± 0.5(0.3) /3 ± 0.7 (0.4) | 9 ± 0.2 (0.1) | 3 ± 0.4 (0.2) /9 ± 0.2 (0.1) | 5 ± 0.3 (0.2) /8 ± 0.2 (0.1) | |
| % of change | 8.3 | 0.0 /0.0 | 0.0 /0.0 | 40 /40 | 0.0 /0.0 | 22.2 | 0.0 /0.0 | 40 /25 | |
| ( | 0.288 | 1.000 /1.000 | 1.000 /1.000 | <0.001** /0.005* | 1.000 /1.000 | 0.014* | 1.000 /1.000 | 0.004* /0.003* | |
| 4/ | Before | 5 ± 0.4 (0.2) | 3 ± 0.5(0.3) /3 ± 0.4 (0.2) | 3 ± 0.2 (0.1) /3 ± 0.4 (0.2) | 3.5 ± 0.5(0.3) /10 ± 0.6 (0.3) | 3 ± 0.3 (0.2) /7 ± 0.7 (0.4) | 7.5 ± 0.5(0.3) | 3 ± 0.7 (0.4) /10 ± 0.2 (0.1) | 3.5 ± 0.4 (0.2) /3.5 ± 0.5(0.3) |
| After | 5 ± 0.6 (0.3) | 5 ± 0.3 (0.2) /6 ± 0.6 (0.3) | 5 ± 0.4 (0.2) /6 ± 0.2 (0.1) | 4 ± 0.5(0.3) /11 ± 0.8 (0.5) | 3 ± 0.8 (0.5) /7 ± 0.2 (0.1) | 9.5 ± 0.5(0.3) | 5 ± 0.5(0.3) /13 ± 0.4 (0.2) | 4 ± 0.2 (0.1) /5.5 ± 0.3 (0.2) | |
| % of change | 0.0 | 40 /50 | 40 /50 | 12.5 /9.1 | 0.0 /0.0 | 21.1 | 40 /23.1 | 12.5 /36.4 | |
| ( | 1.000 | 0.004*/ 0.002* | <0.001** / <0.001** | 0.288 /0.158 | 1.000 /1.000 | 0.008* | 0.016* / <0.001** | 0.125 /0.004* | |
| 8/ | Before | 3 ± 0.9 (0.5) | 3 ± 0.2 (0.1)/3 ± 0.5(0.3) | 4.5 ± 0.4 (0.2) /10 ± 0.2 (0.1) | 8 ± 0.4 (0.2) /12 ± 0.2 (0.1) | 6 ± 0.3 (0.2) /6 ± 0.5(0.3) | 8.5 ± 0.5(0.3) | 4.5 ± 0.5(0.3) /11 ± 0.2 (0.1) | 8 ± 0.2 (0.1) /12 ± 0.4 (0.2) |
| After | 5 ± 0.3 (0.2) | 5 ± 0.4 (0.2)/6 ± 0.2 (0.1) | 6.5 ± 0.2 (0.1)/13 ± 0.5(0.3) | 9 ± 0.2 (0.1) /13.5 ± 0.5(0.3) | 7 ± 0.4 (0.2)/8 ± 0.2 (0.1) | 12 ± 0.3 (0.2) | 6 ± 0.2 (0.1) /13.5 ± 0.5(0.3) | 9 ± 0.1 (0.1) /14 ± 0.2 (0.1) | |
| % of change | 40 | 40 /50 | 30.8 /23.1 | 11.1 /11.1 | 14.3 /25 | 29.2 | 25 /18.5 | 11.1 /14.3 | |
| ( | 0.22* | <0.001** / <0.001** | <0.001** / <0.001** | 0.018* /0.008* | 0.026* /0.003* | <0.001** | 0.008* / <0.001** | <0.001** / <0.001** | |
| 9/ | Before | 3 ± 0.3 (0.2) | 3 ± 0.5(0.3) /3 ± 0.2 (0.1) | 3 ± 0.4 (0.2) /9 ± 0.2 (0.1) | 3 ± 0.2 (0.1) /8 ± 0.3 (0.2) | 8 ± 0.2 (0.1) /8 ± 0.5(0.3) | 5.5 ± 0.5(0.3) | 3 ± 0.2 (0.1) /8 ± 0.4 (0.2) | 3 ± 0.2 (0.1) /7 ± 0.1 (0.1) |
| After | 4.5 ± 0.5(0.3) | 4.5 ± 0.5(0.3) /5 ± 0.2 (0.1) | 5 ± 0.2 (0.1) /11 ± 0.4 (0.2) | 5 ± 0.5(0.3) /11 ± 0.2 (0.1) | 9 ± 0.2 (0.1) /10 ± 0.3 (0.2) | 6.5 ± 0.3 (0.2) | 5 ± 0.1 (0.1) /10 ± 0.2 (0.1) | 5 ± 0.5(0.3) /10 ± 0.1 (0.1) | |
| % of change | 33.3 | 33.3 /40 | 40 /18.2 | 40 /22.3 | 11.1 /20 | 15.4 | 40 /20 | 40 /30 | |
| ( | 0.011* | 0.021* / <0.001** | <0.001** / <0.001** | 0.003* / <0.001** | 0.004* /0.004* | 0.041* | <0.001** / <0.001** | 0.003* / <0.001** | |
| 13/ | Before | 4 ± 0.1 (0.1) | 3 ± 0.2 (0.1) /3 ± 0.5(0.3) | 7 ± 0.1 (0.1) /11 ± 0.4 (0.2) | 6 ± 0.2 (0.1) /11 ± 0.4 (0.2) | 6 ± 0.2 (0.1) /6 ± 0.1 (0.1) | 10 ± 0.2 (0.1) | 7 ± 0.1 (0.1) /12 ± 0.2 (0.1) | 6 ± 0.1 (0.1) /10 ± 0.2 (0.1) |
| After | 4 ± 0.5(0.3) | 4 ± 0.1 (0.1) /4 ± 0.3 (0.2) | 8.5 ± 0.4 (0.2)/13 ± 0.2 (0.1) | 6.5 ± 0.1 (0.1) /12 ± 0.1 (0.1) | 6 ± 0.2 (0.1) /7 ± 0.3 (0.2) | 12 ± 0.3 (0.2) | 8.5 ± 0.1 (0.1) /14 ± 0.2 (0.1) | 6.5 ± 0.2 (0.1)/10.5 ± 0.3 (0.2) | |
| % of change | 0.0 | 25 /25 | 17.6 /15.4 | 7.5 /8.3 | 0.0 /14.3 | 16.7 | 17.6 /14.3 | 7.5 /4.8 | |
| ( | 1.000 | <0.001** / 0.041* | 0.003* / <0.001** | 0.018* /0.014* | 1.000 /0.005* | <0.001** | <0.001** / <0.001** | 0.018* /0.074 | |
DDST Double disk synergy test, MDDT Modified double disk synergy test p-value significant <0.05
AMC (20/10 μg) = Amoxicillin /clavulanic Acid CTX (30 μg) = Cefotaxime p-value non significant > 0.05
CAZ (30 μg) = Ceftazidime FEP (30 μg) = Cefepime p-value highly significant <0.001**
ATM (30 μg) = Aztreonam TZP (100/10 μg) = Piperacillin / tazobactam
Effect of in vitro gamma irradiation on MIC of different antibiotics alone or combined with permeabilizers of non-beta lactamase producer bacterial isolates
| Antibiotics | MICs (mg/L) before irradiation | MICs (mg/L) after irradiation | ||||
|---|---|---|---|---|---|---|
| Bacterial species | Ab-Alone | +Gallic acid | +Thymol | Alone | +Gallic acid | +Thymol |
|
| ||||||
| CTX | 64 | 8 | 4 | 64 | 8 | 4 |
| CFP | 64 | 16 | 16 | 128 | 32 | 32 |
| E | 128 | 32 | 32 | 256 | 64 | 64 |
|
| ||||||
| CTX | 32 | 8 | 8 | 32 | 8 | 8 |
| CFP | 32 | 8 | 8 | 64 | 16 | 16 |
| E | 64 | 32 | 16 | 128 | 64 | 32 |
|
| ||||||
| CTX | 128 | 32 | 32 | 128 | 32 | 32 |
| CFP | 128 | 32 | 32 | 256 | 64 | 64 |
| E | 128 | 128 | 64 | 256 | 256 | 128 |
|
| ||||||
| CTX | 8 | 2 | 4 | 8 | 2 | 4 |
| CFP | 32 | 16 | 8 | 32 | 16 | 8 |
| E | 64 | 16 | 16 | 64 | 16 | 16 |
CTX Cefotaxime, CFP Cefoperazone, E Erythromycin
Evaluation of MICs of certain antibiotics alone and with beta lactamase inhibitors alone (ECG) or in combination with gallic acid or thymol and selected permeabilizers before and after in vitro gamma irradiation
| Antibiotic (Ab) | MICs (mg/L) before irradiation | MICs (mg/L) after irradiation | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ab-alone | +ECG | +ECG+ Gallic acid | +ECG +Thymol | antibiotic disc with beta-lactamase inhibitors | Ab- Alone | +ECG | +ECG+ Gallic acid | +ECG + Thymol | antibiotic disc with beta-lactamase inhibitors | |
| Bacterial beta lactamase producer | ||||||||||
|
| ||||||||||
| CFP | 64 | 64 | 8 | 4 | a32 | 64 | 64 | 8 | 4 | a32 |
| PRL | 128 | 128 | 16 | 4 | b16 | 128 | 128 | 16 | 4 | b16 |
|
| ||||||||||
| CFP | 128 | 128 | 16 | 8 | 64 | 128 | 128 | 16 | 8 | 64 |
| PRL | 128 | 128 | 8 | 8 | 64 | 128 | 128 | 8 | 8 | 64 |
|
| ||||||||||
| CFP | 32 | 32 | 4 | 4 | 16 | 64 | 64 | 8 | 8 | 32 |
| PRL | 64 | 64 | 4 | 4 | 0.5 | 128 | 128 | 8 | 8 | 1 |
Ab Antibiotic, ECG Epigallocatechin gallate, CFP Cefoperazone
PRL = Piperacillin. SCF = Cefoperazone/ sulbactum. b TZP = Piperacillin/ tazobactam
Evaluation of MICs of certain antibiotics alone and in the presence of beta lactamase inhibitors alone (quercetin) or in combination with gallic acid or thymol and selected permeabilizers before and after in vitro gamma irradiation
| Antibiotics (Ab) | MICs (mg/L) before irradiation | MICs (mg/L) after irradiation | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ab-alone | +Q | +Q + Gallic acid | +Q + Thymol | Antibiotic disc with beta-lactamase inhibitors | Ab-alone | +Q | +Q + Gallic acid | +Q + Thymol | antibiotic disc with beta-lactamase inhibitors | |
| Bacterial beta lactamase producer | ||||||||||
|
| ||||||||||
| CFP | 64 | 32 | 8 | 2 | a32 | 64 | 32 | 8 | 2 | 32 |
| PRL | 128 | 32 | 8 | 4 | b16 | 128 | 32 | 8 | 4 | 16 |
|
| ||||||||||
| CFP | 128 | 32 | 8 | 2 | 64 | 128 | 32 | 8 | 2 | 64 |
| PRL | 128 | 64 | 8 | 8 | 64 | 128 | 64 | 8 | 8 | 64 |
|
| ||||||||||
| CFP | 32 | 16 | 8 | 4 | 16 | 64 | 64 | 32 | 8 | 32 |
| PRL | 64 | 32 | 2 | 1 | 0.5 | 128 | 64 | 4 | 2 | 1 |
Q Quercetin, CFP Cefoperazone, PRL Piperacillin
aSCF = Cefoperazone/ sulbactum b TZP = Piperacillin/ tazobactam
Effects of different lytic agents on the outer membrane permeability of Pseudomonas aeruginosa10 / Escherichia coli3 pretreated with permeabilizers and gamma irradiation
| Lytic agent | Conc. | Relative turbidity (%) | |||
|---|---|---|---|---|---|
| Control- | Gallic acid | Thymol | Radiation | ||
| Lysozyme | 10 μg/mL | 100 ± 1 /101 ± 1 | 99 ± 1/ 92 ± 1 | 100 ± 1/ 98 ± 0.6 | 100 ± 0.6/ 101 ± 2 |
| Triton X-100 | 0.1% | 100 ± 2 /103 ± 3 | 93 ± 3/86 ± 3 | 96 ± 1/ 90 ± 3 | 100 ± 1/ 101 ± 1.2 |
| Triton X-100 | 1% | 99 ± 3 /105 ± 0.6 | 81 ± 1/77 ± 2 | 84 ± 3/ 74 ± 4 | 99 ± 2/ 103 ± 3 |
| SDS | 0.1% | 92 ± 1 /91 ± 2 | 58 ± 2/ 60 ± 1 | 60 ± 3/ 59 ± 3 | 92 ± 1/ 91 ± 5 |
| SDS | 1% | 78 ± 0.6 / 80 ± 2 | 26 ± 1/ 42 ± 2 | 28 ± 2/ 50 ± 0.6 | 79 ± 2/ 82 ± 2 |
The value of control cells without lytic agents was set at 100%
Fig. 1SDS-PAGE of Proteinase K-treated cell-free supernatants of Escherichia coli3 (silver staining). Lanes: 1, untreated (control); 2, irradiated supernatant; 3, thymol supernatant; 4, gallic acid supernatant; 5, EDTA supernatant; 6, chitosan supernatant
Beta lactamase assays in the presence of permeabilizer (thymol) and natural beta lactamase inhibitor (quercetin) for irradiated and non-irradiated Pseudomonas aeruginosa8 / Escherichia coli2
| Conc. | control | ||||||
|---|---|---|---|---|---|---|---|
| aCefoperazone | aCefoperazone + thymol | aCefoperazone +thymol+quercetin | |||||
| Before | After | Before | After | Before | After | ||
| 128/64 | 0.271/0.273 | 0.123 ± 0.001/ 0.148 ± 0.001 | 0.142 ± 0.001/ 0.161 ± 0.002 | 0.037 ± 0.002/ 0.049 ± 0.006 | 0.044 ± 0.0006/ 0.053 ± 0.002 | 0.196 ± 0.002/ 0.215 ± 0.001 | 0.211 ± 0.0006/ 0.221 ± 0.001 |
| 64 /32 | 0.263 /0.263 | 0.119 ± 0.0006/ 0.139 ± 0.002 | 0.133 ± 0.003/ 0.160 ± 0.001 | 0.030 ± 0.001/ 0.048 ± 0.001 | 0.040 ± 0.001/ 0.050 ± 0.0005 | 0.183 ± 0.003/ 0.206 ± 0.001 | 0.203 ± 0.001/ 0.213 ± 0.0006 |
| 32/16 | 0.256/0.258 | 0.115 ± 0.001/ 0.128 ± 0.0006 | 0.130 ± 0.0006/ 0.148 ± 0.002 | 0.02 ± 0.001/ 0.045 ± 0.001 | 0.039 ± 0.0006/ 0.048 ± 0.002 | 0.179 ± 0.001/ 0.197 ± 0.001 | 0.20 ± 0.006/ 0.203 ± 0.001 |
Control = Cefoperazone antibiotic in a solution of B-CHR-TMB
a Mean results of triplicate experiments